Effect of Transdermal Estradiol and Oral Conjugated Estrogen on C-Reactive Protein in Retinoid-Placebo Trial in Healthy Women

Background—The increase in C-reactive protein (CRP) during oral conjugated equine estrogen (CEE) may explain the initial excess of cardiovascular disease observed in clinical studies. Because the effect of transdermal estradiol (E2) on CRP is unclear, we compared CRP changes after 6 and 12 months of transdermal E2 and oral CEE in a randomized 2×2 retinoid-placebo trial. Methods and Results—A total of 189 postmenopausal women were randomized to 50 &mgr;g/d transdermal E2 and 100 mg BID of the retinoid fenretinide (n=45), 50 &mgr;g/d transdermal E2 and placebo (n=49), 0.625 mg/d oral CEE and 100 mg BID fenretinide (n=46), or 0.625 mg/d oral CEE and placebo (n=49) for 1 year. Sequential medroxyprogesterone acetate was added in each group. Relative to baseline, CRP increased by 10% (95% CI −9% to 33%) and by 48% (95% CI 22% to 78%) after 6 months of transdermal E2 and oral CEE, respectively. The corresponding figures at 12 months were 3% (95% CI −14% to 23%) for transdermal E2 and 64% (95% CI 38% to 96%) for oral CEE. Fenretinide did not change CRP levels at 6 and 12 months relative to placebo. Relative to oral CEE, the mean change in CRP after 12 months of transdermal E2 was −48% (95% CI −85% to −7%, P =0.012), whereas fenretinide was associated with a mean change of −1% (95% CI −34% to 40%, P =0.79) compared with placebo. Conclusions—In contrast to oral CEE, transdermal E2 does not elevate CRP levels up to 12 months of treatment. The implications for early risk of coronary heart disease require further studies.

[1]  A. Wakatsuki,et al.  Effect of transdermal estradiol and oral conjugated equine estrogen on C-reactive protein in retinoid-placebo trial in healthy women. , 2003, Circulation.

[2]  J. Manson,et al.  Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. , 2002, JAMA.

[3]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[4]  R. Karas,et al.  The protective effects of estrogen on the cardiovascular system. , 2002, The New England journal of medicine.

[5]  R. Saucedo,et al.  Transdermal Estradiol in Menopausal Women Depresses Interleukin-6 without Affecting Other Markers of Immune Response , 2002, Gynecologic and Obstetric Investigation.

[6]  M. Meredith,et al.  A method to assess the proportion of treatment effect explained by a surrogate endpoint , 2001, Statistics in medicine.

[7]  N Rifai,et al.  Differential effects of E and droloxifene on C-reactive protein and other markers of inflammation in healthy postmenopausal women. , 2001, The Journal of clinical endocrinology and metabolism.

[8]  V. Pasceri,et al.  C-reactive protein: linking inflammation to cardiovascular complications. , 2001, Circulation.

[9]  J. Manson,et al.  C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. , 2001, JAMA.

[10]  N Rifai,et al.  Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. , 2001, JAMA.

[11]  F. Grodstein,et al.  Postmenopausal Hormone Use and Secondary Prevention of Coronary Events in the Nurses' Health Study: A Prospective, Observational Study , 2001, Annals of Internal Medicine.

[12]  P. Ridker,et al.  High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. , 2001, Circulation.

[13]  M. Taskinen,et al.  Effects of Oral and Transdermal Estrogen Replacement Therapy on Markers of Coagulation, Fibrinolysis, Inflammation and Serum Lipids and Lipoproteins in Postmenopausal Women , 2001, Thrombosis and Haemostasis.

[14]  M. Thun,et al.  Effect of body mass on the association between estrogen replacement therapy and mortality among elderly US women. , 2001, American journal of epidemiology.

[15]  M. Taskinen,et al.  Differential Effects of Oral and Transdermal Estrogen Replacement Therapy on Endothelial Function in Postmenopausal Women , 2000, Circulation.

[16]  R. Cannon,et al.  Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. , 2000, Journal of the American College of Cardiology.

[17]  N. Sattar,et al.  C-reactive protein and hormone replacement therapy. , 2000, Circulation.

[18]  S. Fichtlscherer,et al.  Elevated C-Reactive Protein Levels and Impaired Endothelial Vasoreactivity in Patients With Coronary Artery Disease , 2000, Circulation.

[19]  P. Ridker,et al.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.

[20]  E. Vittinghoff,et al.  Postmenopausal Hormone Therapy Increases Risk for Venous Thromboembolic Disease: The Heart and Estrogen/progestin Replacement Study , 2000, Annals of Internal Medicine.

[21]  M. Visser,et al.  Elevated C-reactive protein levels in overweight and obese adults. , 1999, JAMA.

[22]  M. Sporn,et al.  Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. , 1999, Journal of the National Cancer Institute.

[23]  E. Barrett-Connor,et al.  Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. , 1999, Circulation.

[24]  N. Sattar,et al.  Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes , 1999, The Lancet.

[25]  E. Vittinghoff,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[26]  R Peto,et al.  Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. , 1998, JAMA.

[27]  N. Wintfeld,et al.  Postmenopausal hormone therapy and mortality. , 1997, The New England journal of medicine.

[28]  R. Cannon,et al.  Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. , 1997, The New England journal of medicine.

[29]  L. Nachtigall.  Emerging delivery systems for estrogen replacement: aspects of transdermal and oral delivery. , 1995, American journal of obstetrics and gynecology.

[30]  T. Lint,et al.  Structure and function of the pentraxins. , 1995, Current opinion in immunology.

[31]  D. Altman,et al.  Statistics Notes: Some examples of regression towards the mean , 1994 .

[32]  E. Catsafados,et al.  The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients. , 1993, Cancer research.

[33]  P. Rousseeuw.  Least Median of Squares Regression , 1984 .

[34]  R. Tracy,et al.  The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. , 2000, The Journal of clinical endocrinology and metabolism.

[35]  G. Fitzmaurice.  Regression to the mean - some examples of regression towards the mean , 2000 .

[36]  T. Nakamura,et al.  Hepatocyte growth factor and retinoic acid exert opposite effects on synthesis of type 1 and type 2 acute phase proteins in rat hepatoma cells. , 1995, The international journal of biochemistry & cell biology.